No Data
No Data
No Data
“Innova”, a provider of integrated solutions for non-vascular interventional procedures, submitted a listing to the Hong Kong Stock Exchange and received investment from Temasek and Ko Lin
Innovent submitted a prospectus to the Hong Kong Stock Exchange on June 14, 2023 and plans to be listed on the Hong Kong Main Board. The company is an integrated solution provider for non-vascular interventional procedures. Revenue in 2022 was 340 million yuan (year-on-year growth rate of 33.51%), with a net loss of 220 million yuan.
Weekly IPO | I think Yunfutu's dark market rose more than 83%, and Yaduo rose more than 17% on the first day of listing
This week, Innovie, Metz Health and Shenghui Clean submitted reports to the Hong Kong Stock Exchange; Liqin Resources reported; Duosangyun Futu closed up 83.67% in the dark market, earning HK$3,280 each. Without saying that Futu closed 8.4% in the dark market, it closed up 5.47% on the first day of listing.
News of new shares: Ying Nuowei reports that the Hong Kong Stock Exchange focuses on the sale of medical equipment such as endoscopes
Zhitong Financial APP learned that according to the disclosure of the HKEx on April 29th, Shanghai Yingwei Medical Devices Co., Ltd. submitted the form to the main board of the HKEx, with Goldman Sachs Group and China International Capital Corporation as co-sponsors. Invid is China's leading provider of integrated solutions for non-vascular interventional surgery with a global vision. According to CIC, since its establishment in 2009, the company has established a leading proprietary technology platform and formed economies of scale, making it a major medical specialty capable of providing non-vascular interventional surgery for urology, gastroenterology, hepatobiliary surgery, respiratory, thoracic surgery, otorhinolaryngology, gynecology and general surgery.
CSRC: materials have been received for overseas initial public offering of shares by Shanghai Yingnuowei Medical Devices Co., Ltd.
Zhitong Financial APP learned that on March 16, the Securities Regulatory Commission announced the progress of the "approval of overseas initial public offering of shares (including common shares, preferred shares and other derivative forms of shares and stocks)" of Shanghai Yinuowei Medical Devices Co., Ltd., which has reached the stage of receiving materials.
No Data